PARATEK PHARMACEUTICALS, INC. PRTK Income Statement

Paratek pharmaceuticals, inc. (PRTK)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
License and royalty revenue
-	-	-	-	-	-	-	-	-	-	-	-	18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net revenue
7,920	8,967	3,934	2,045	1,598	17,017	50	40	10	-	12	7,514	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development collaborations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	4,000	0	294	48	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty Revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	316	418	481	482	93	190	493	0	-	-	-	-	-	-
Gross license fee revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	417	625	3,125	3,125	3,125	3,125
Gross milestone revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	10,000	0	0	-	-	-	-	-	-
Gross milestone revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Other Revenue, Net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	50	-	-	0	250	0	0	-	0	-	-	-	-
Advertising expense - Purdue Pharma
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	140	86	283	6,312	1,429	0	0	0	-	-	-	-	-	-
Net revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	176	382	198	-5,830	-1,336	10,440	493	0	-	625	3,125	-	-	-
Expenses:
Cost of product revenue
1,471	1,753	958	567	206	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
6,389	9,133	8,350	10,679	11,392	11,802	16,040	14,802	14,864	14,224	12,112	15,079	18,657	19,703	17,334	22,135	24,288	15,209	17,817	10,998	6,741	2,650	1,001	837	526	1,753	2,410	898	1,843	2,918	3,057	2,859	2,357	3,351	2,668	2,763	2,491	2,885	2,407
Selling, general and administrative
23,638	21,263	23,636	20,920	23,316	25,263	13,610	12,912	11,873	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
-	-	-	-	-	-	-	-	-	11,667	8,219	8,716	8,363	6,510	5,949	7,602	6,339	5,641	5,795	4,281	4,271	1,983	2,074	1,338	453	3,941	2,658	3,030	2,802	2,265	2,483	2,731	2,784	4,140	2,919	2,582	2,544	2,984	2,769
Impairment of intangible assets
-	-	-	-	-	-	21	86	-	-	-	682	-	-	-	-	-	99	0	0	2,761	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in fair value of contingent consideration
-	-	-	-	-	-14	-11	-31	-15	-13	-22	-318	-231	-295	-170	15	105	-580	-240	400	-3,140	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes receivable impairment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill impairment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,962	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
31,498	32,149	32,944	32,166	34,914	37,051	29,660	27,769	26,722	25,939	20,309	24,159	26,789	25,918	23,113	29,752	30,732	20,369	23,372	15,679	10,633	5,911	3,075	2,175	979	5,694	5,068	6,890	4,645	5,183	5,540	5,590	5,141	7,491	5,587	5,345	5,035	5,869	5,176
Loss from operations
-23,578	-23,182	-29,010	-30,121	-33,316	-20,034	-29,610	-27,729	-26,712	-20,867	-20,297	-16,645	-26,771	-25,889	-23,113	-29,752	-30,732	-20,369	-23,372	-15,679	-10,633	-1,911	-3,075	-1,881	-931	-5,518	-4,686	-6,692	-10,475	-6,519	4,900	-5,097	-5,141	5,328	-4,962	-2,220	-1,910	-2,744	-2,051
Other income and expenses:
Interest income
705	701	992	935	946	969	922	894	475	399	389	349	240	281	309	288	191	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25	37
Interest expense
4,826	4,626	4,560	3,991	3,226	3,191	3,383	2,904	1,507	1,413	1,408	1,126	1,132	855	820	818	730	698	47	25	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	4
Interest expense, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-158	-384	-171	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on mark-to-market of notes and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5	0	0	-115	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other gains (losses), net
82	-	-36	-24	-14	-	-12	6	-6	-11	-8	-8	-7	-	-4	-1	-	-40	-2	5	0	-	0	-5	-	-17	-17	-16	-25	-35	-45	-43	-36	-32	-29	-26	-29	-45	-43
Net loss before provision for income taxes
-	-	-32,614	-33,201	-	-22,288	-32,083	-29,733	-27,750	-	-21,324	-17,430	-	-	-23,628	-30,283	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for income taxes
-	-	0	0	-	502	0	0	0	-	0	753	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other loss, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-27,617	-27,365	-32,614	-33,201	-35,610	-22,790	-32,083	-29,733	-27,750	-21,892	-21,324	-18,183	-27,670	-26,454	-23,628	-30,283	-31,271	-21,107	-23,421	-15,699	-10,633	-11,121	-3,233	-2,270	-1,211	-5,535	-4,703	-6,708	-10,500	-6,554	4,855	-5,140	-5,177	5,296	-4,991	-2,246	-1,939	-2,767	-2,061
Unaccreted dividends on convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	243	745	737	202	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11,364	-3,978	-3,007	-1,413	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash distribution declared per common share (usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-
Earnings Per Share, Basic (usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.37	-	-	-	-
Earnings Per Share, Diluted (usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.37	-	-	-	-
Weighted Average Number of Shares Outstanding, Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,522	-	-	-	-
Weighted Average Number of Shares Outstanding, Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,522	-	-	-	-
Other comprehensive loss
Unrealized gain on available-for-sale securities, net of tax
397	-74	-68	144	200	201	-103	-47	-21	-78	16	-42	-38	-30	-20	33	1	-	0	0	0	-	-	-	-	-	40	-16	0	-	-	-	-	-	-	-	-	-	-
Weighted average shares outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,488	13,461	13,426	13,402
Comprehensive loss
-27,220	-27,439	-32,682	-33,057	-35,410	-22,589	-32,186	-29,780	-27,771	-21,970	-21,308	-18,225	-27,708	-26,484	-23,648	-30,250	-31,270	-21,107	-23,421	-15,699	-10,633	-	-	-	-	-5,544	-4,663	-6,724	-10,500	-6,552	4,862	-5,142	-5,206	5,289	-4,996	-2,222	-1,924	-	-
Net loss per share:
Basic and diluted net loss per common share
-0.66	-0.81	-1.00	-1.02	-1.10	-0.71	-1.01	-0.94	-0.91	-0.75	-0.77	-0.66	-1.14	-1.00	-1.04	-1.69	-1.78	-1.26	-1.33	-0.96	-0.74	42.96	-29.48	-42.23	20.93	-0.29	-0.25	-0.36	-0.56	-	-	-	-	-	-	-0.17	-0.14	-0.21	-0.15
Weighted average common stock outstanding Basic and diluted
41,641	33,796	32,590	32,446	32,334	32,162	31,742	31,581	30,566	27,988	27,776	27,347	24,196	22,873	22,627	17,895	17,615	17,655	17,561	16,372	14,418	9,840	135	71	67	18,842	18,782	18,757	18,703	-	-	-	-	-	-	-	-	-	-
Product Revenue, Net [Member]
Net revenue
7,303	5,415	3,053	1,702	1,347	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Government Contract Service Revenue [Member]
Net revenue
337	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration and Royalty Revenue [Member]
Net revenue
280	3,552	881	343	251	17,017	50	40	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-